Last reviewed · How we verify
Lidocaine Digital Nerve Block
Lidocaine Digital Nerve Block, developed by the University of California, San Francisco, is a marketed local anesthetic used for digital nerve block procedures. The key composition patent expires in 2028, providing a strong barrier to generic competition until then. The primary risk is the potential for increased competition once the patent expires.
At a glance
| Generic name | Lidocaine Digital Nerve Block |
|---|---|
| Sponsor | University of California, San Francisco |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Effect of Injectable Hyaluronic Acid (HYADENT BG (HA)) on Bone Healing in Extraction Sockets (NA)
- Pain and Anxiety in Pediatric Dentistry: Computer-Controlled vs. Traditional Anesthesia (NA)
- Effectiveness of Digital Anesthesia Versus Conventional Techniques in Reducing Pain and Anxiety in Children (NA)
- Intercostal Nerve Block for Pain Management After Uniportal Video-assisted Thoracoscopic Surgeries (NA)
- Propagation Waves in Tactile Material Perception (NA)
- Determination of the Duration of Action of a Lidocaine and a Bupivacaine Digital Nerve Block in Human Volunteers (PHASE4)
- The Skin Wrinkle Test: a Simple Clinical Test of Regional Block Success (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Lidocaine Digital Nerve Block CI brief — competitive landscape report
- Lidocaine Digital Nerve Block updates RSS · CI watch RSS
- University of California, San Francisco portfolio CI